based on the loosening of public health restrictions and renewed access to healthcare facilities, the company anticipates reported net sales in the range of $num-one million to $num-two million.
adjusted ebitda, similar to the prior year in the range of $num-one million to $num-two million, and free cash flow usage, in line with the prior year in the range of $num-three million to $num-four million.
adjusted ebitda, similar to the prior year in the range of $num-one million to $num-two million, and free cash flow usage, in line with the prior year in the range of $num-three million to $num-four million.